



Journal	Year Of Publication	Patients Included for Primary Analysis	Quartile Number	Report of SGA	Number of Reported SGA	Adjustment for Multiple Testing	Specification Time of SGA	Study Protocol Provided	SGA Prespecified within Protocol	Test for Interaction Reported	Significant Heterogeneity of Treatment Effects	Type of Intervention under Study	Trial Design	Result of Primary Statistical Analysis
1	2	3206	4	1	30	0	1	1	1	1	1	1	0	0
1	2	7513	4	1	36	0	1	1	1	1	1	1	1	0
1	2	9013	4	1	10	0	0	1	0	1	0	3	1	0
1	2	3102	4	1	6	0	1	1	1	1	0	2	1	0
1	2	13199	4	1	15	0	1	1	1	1	0	1	1	0
1	2	3876	4	1	13	1	1	1	1	1	0	1	1	1
1	2	12705	4	1	42	0	1	1	1	1	1	1	1	1
1	2	9340	4	1	14	0	1	1	1	1	1	1	1	1
1	2	3297	4	1	14	0	1	1	1	1	0	1	0	1
1	2	24081	4	1	12	0	1	1	1	1	0	1	0	1
2	1	130	1	0				0				2	0	0
2	1	47	1	0				0				1	1	1
2	1	101	1	0				0				1	1	1
2	1	314	2	0				0				1	1	1
2	1	428	2	0				0				4	1	1
2	1	399	2	0				0				1	1	1
2	1	2500	3	0				0				2	0	1
2	1	4146	4	0				0				4	1	1
2	1	168	1	1	2	0	1	0		1	1	1	0	1
2	1	627	2	1	7	0	0	0		1	1	3	1	1
2	1	877	2	1	30	0	1	0		1	0	1	1	1
2	1	2104	3	1	35	0	1	0		1	0	4	1	1
2	1	8404	4	1	40	0	1	0		1	1	3	1	1
2	1	2999	4	1	11	0	1	0		1	0	3	0	1
2	1	5380	4	1	8	0	0	0		1	0	1	0	1
2	2	109	1	0				0				1	1	1
2	2	501	2	0				0				3	1	0
2	2	448	2	0				0				1	1	1
2	2	190	1	1	3	0	1	0		1	0	1	1	0
2	2	243	1	1	20	0	3	0		1	1	1	1	0
2	2	457	2	1	6	0	0	0		1	1	3	1	1
2	2	450	2	1	2	0	0	0		1	0	4	0	1
2	2	2604	3	1	14	0	1	0		1	0	1	1	0
2	2	1215	3	1	7	0	2	0		1	0	3	1	0
2	2	2199	3	1	46	0	0	0		0	0	1	1	0
2	2	1184	3	1	1	0	0	0		0	0	3	0	1
2	2	3232	4	1	24	0	0	0		1	1	1	1	0
2	2	3514	4	1	22	0	1	0		1	0	3	0	1
3	1	160	1	0				0				4	1	0
3	1	22	1	0				0				1	1	0
3	1	253	1	0				0				1	1	0
3	1	248	1	0				0				4	1	1
3	1	119	1	0				0				3	1	1
3	1	160	1	0				0				4	1	1
3	1	47	1	0				0				1	1	1
3	1	151	1	0				0				1	1	1
3	1	322	2	0				0				3	0	1
3	1	2291	3	0				0				3	0	1
3	1	400	2	1	21	0	3	0		1	0	3	1	0
3	1	441	2	1	10	0	0	0		1	1	4	1	0
3	1	363	2	1	12	0	1	0		1	0	1	1	0
3	1	300	2	1	1	0	0	0		1	0	3	0	1
3	1	617	2	1	9	0	2	0		1	0	1	1	1
3	1	2086	3	1	1	0	1	0		1	1	4	1	1
3	1	7173	4	1	6	0	0	0		0	0	4	1	1
3	2	120	1	0				0				1	1	0
3	2	203	1	0				0				4	1	1
3	2	203	1	0				0				1	1	1
3	2	50	1	0				0				1	1	1

Journal	Year Of Publication	Patients Included for Primary Analysis	Quartile Number	Report of SGA	Number of Reported SGA	Adjustment for Multiple Testing	Specification Time of SGA	Study Protocol Provided	SGA Prespecified within Protocol	Test for Interaction Reported	Significant Heterogeneity of Treatment Effects	Type of Intervention under Study	Trial Design	Result of Primary Statistical Analysis
3	2	240	1	0				0				4	1	1
3	2	51	1	0				0				4	1	1
3	2	246	1	0				0				4	1	1
3	2	302	2	0				0				1	1	1
3	2	358	2	0				0				1	1	1
3	2	1258	3	0				0				1	0	1
3	2	151	1	1	2	0	0	0		0	0	4	1	1
3	2	60	1	1	8	0	1	0		1	1	4	1	1
3	2	1230	3	1	7	0	0	0		1	0	1	1	0
3	2	1198	3	1	6	0	1	0		0	0	4	1	0
3	2	1372	3	1	14	0	1	0		1	1	4	1	1
3	2	7402	4	1	2	0	0	0		1	0	1	1	0

**Journal:** 1 = The New England Journal of Medicine  
2 = The Lancet  
3 = Circulation

**Year of publication:** 1 = 2015  
2 = 2016

**Report of SGA** 0 = No SGA Reported  
1 = SGA Reported

**Adjustment for Multiple Testing:** 0 = No Adjustment made  
1 = Adjustment made

**Specification Time of SGA** 0 = Unclear  
1 = Prespecified  
2 = Post-hoc  
3 = Prespecified and post-hoc

**Study Protocol Provided** 0 = No  
1 = Yes

**SGA Prespecified within Protocol** 0 = SGA not Prespecified within Protocol  
1 = SGA Prespecified within Protocol

**Test for Interaction Reported** 0 = No Report of Test for Interaction  
1 = Report of Test for Interaction

**Significant Heterog. of Treatment Effects** 0 = No Significant Heterogeneity  
1 = Significant Heterogeneity

**Type of Intervention under Study** 1 = Pharmaceutical  
2 = Surgical  
3 = Endovascular  
4 = Others

**Trial Design** 0 = Non-Inferiority-Trial  
1 = Superiority-Trial

**Result of Primary Statistical Analysis** 0 = Not Significant  
1 = Significant